Given elevated LAT1 expression on metastatic cancer in general (i.e., not necessarily specific to BrM), if QBS72S were to prove efficacious in BrM, it should be likewise active against the patient’s systemic disease. Here, SLC7A5 is linked to metastatic malignant neoplasm.